Retatrutide
Triple agonist (GLP-1/GIP/Glucagon) — next-gen weight loss
개요
Retatrutide is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. It represents the next generation of obesity pharmacotherapy.
Key Information
Mechanism
Triple agonism of GLP-1 (appetite suppression), GIP (insulin sensitization), and glucagon (fat oxidation and thermogenesis) receptors.
Benefits
- Up to 24.2% weight loss
- Triple hormone agonist
- Highest efficacy in trials
Side Effects
- Nausea
- Diarrhea
- Vomiting
Contraindications
- Not studied in pregnancy
Evidence Summary
Phase 2 showed 24.2% weight loss at 48 weeks. Phase 3 TRIUMPH trials ongoing.
Research
Phase 2 trials showed up to 24.2% weight loss at 48 weeks, the highest of any peptide in clinical trials.
View ResearchSafety
Similar GI side effects to GLP-1 class. Still in Phase 3 development.
Legal Status
Investigational — not yet FDA-approved. In Phase 3 TRIUMPH trials.
Write a Review
Rating Breakdown
리뷰
Started taking Reta in May 2026 and 3 months later I'm down 33 lbs. Taking 6mg but weight loss has gotten slower. Thinking about going up to 8mg. The triple agonist mechanism is unreal.
Reta reversed my type 2 diabetes. A1C normalized within 4 months. Also lost 25 lbs. The heart rate increase is real though - monitoring that closely with my doctor.
Down 28 lbs in 4 months. The weight loss is unmatched but increased heart rate is a real side effect. Also noticed it blunted my dopamine - lost interest in unhealthy habits which was actually positive.